Ractigen is a clinical-stage pharmaceutical company utilizing small activating RNA (saRNA) technology to enhance the expression of therapeutic genes in diseased cells. The company focuses on developing first-in-class therapies for previously undruggable diseases, including oncology and neurological disorders.
Funding
$30M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases, including cancers and neurological disorders, are considered "undruggable" because the therapeutic target is not easily modulated by traditional small molecule or antibody drugs. Selectively increasing the expression of specific, therapeutic genes within diseased cells remains a significant challenge.
Solution
Ractigen Therapeutics is developing small activating RNA (saRNA) therapeutics designed to upregulate the expression of endogenous therapeutic genes in diseased cells. Their RNAa technology platform uses short, double-stranded RNA molecules to selectively activate gene transcription, offering a novel approach to treating previously undruggable diseases. By stimulating the production of targeted proteins from within the patient's own cells, Ractigen aims to restore cellular function and combat disease. The company's pipeline includes programs targeting oncology, neurological disorders, neuromuscular disorders, and liver-related indications.
Target Audience
Ractigen's primary focus is on patients with previously undruggable diseases, including those with cancers, neurological disorders, and neuromuscular conditions, as well as the physicians who treat them.
Features
- saRNA technology to selectively turn genes "on" by using short duplex RNA.
- Stimulates the production of targeted endogenous genes.
- Diverse pipeline covering previously undruggable diseases and monogenic disorders.
- Programs in oncology, neurological and neuromuscular disorders, and liver-related indications.
- First patient dosed in Phase I clinical trial for RAG-17 in SOD1-ALS.